



## Facts

Portfolio value	\$163.18 mn
Fund commenced	10 November 2003
Minimum investment	A\$20,000 or NZ\$20,000
Regular Investment Plan (min.)	A\$200 or NZ\$200 per mth/qtr
Income distribution date	Annual, 30 June
Unit valuation	Sydney Business Day
Unit prices	App - 1.9105    Red - 1.9009


## Fees

Entry fee	Nil
Exit fee	Nil
Management Expense Ratio/ Indirect Cost Ratio (MER/ICR)	1.54% per annum (inclusive of investment & administration costs)
Brokerage paid	Nil
Buy/sell spread	0.25%/0.25%

## Performance<sup>1</sup>

	FUND %	MSCI %
1 month	(6.65)	(6.25)
3 months	(3.92)	(10.82)
6 months	1.47	(4.36)
Calendar year to date	(7.28)	(12.16)
1 year	(7.97)	(13.24)
2 years (compound pa)	12.32	6.47
3 years (compound pa)	13.77	14.59
5 years (compound pa)	18.47	21.39
7 years (compound pa)	15.99	15.11
10 years (compound pa)	9.06	7.58
Since inception (compound pa)	8.58	7.93

## Performance graph<sup>2</sup>



Source: Factset and Platinum

## Invested positions<sup>3</sup>

	LONG %	NET %	CURRENCY %
Australia	3.9	3.9	1.7
Belgium	1.0	1.0	
Canada	1.6	1.6	1.6
Denmark	2.2	2.2	2.2
France	7.7	7.7	
Germany	10.1	10.1	
Italy	1.5	1.5	
Japan	2.9	2.9	5.2
Netherlands	1.9	1.9	
Sweden	1.7	1.7	1.7
Switzerland	6.1	6.1	6.1
United Kingdom	8.2	8.2	9.1
United States	37.0	36.2	45.4
	85.8	85.1	
Euro Currency			25.8
Norwegian Krone			0.5
Singapore Dollar			0.7
Cash & Accruals	14.2	14.9	
<b>Total</b>	<b>100.0</b>	<b>100.0</b>	<b>100.0</b>

Long - 53 stocks    Short - 1 stock

## Top ten positions<sup>4</sup>

STOCK	COUNTRY	INDUSTRY	%
Sanofi SA	France	Pharmaceuticals	4.5
AstraZeneca PLC	UK	Health Equip & Servs	3.6
Ipsen SA	France	Pharmaceuticals	3.2
Roche Holding AG	Switzerland	Pharmaceuticals	3.0
Johnson & Johnson	USA	Pharmaceuticals	2.8
Qiagen NV	Germany	Health Equip & Servs	2.8
Gilead Sciences Inc	USA	Biotechnology	2.5
Foundation Medicine Inc	USA	Health Care Providers	2.3
MorphoSys AG	Germany	Biotechnology	2.2
H Lundbeck A/S	Denmark	Pharmaceuticals	2.2

## Industry breakdown<sup>3</sup>

SECTOR	LONG %	NET %
Health Care	85.8	85.1

Platinum Investment Management Limited ABN 25 063 565 006 AFSL 221935, trading as Platinum Asset Management ("Platinum") is the responsible entity and investment manager of the Platinum International Health Care Fund (the "Fund"). The Platinum Trust Product Disclosure Statement No. 10 ("PDS") provides details about the Fund. You can obtain a copy of the PDS from Platinum's website [www.platinum.com.au](http://www.platinum.com.au), or by contacting Investor Services on 1300 726 700 (Australian investors only), or 0800 700 726 (New Zealand investors only), or 02 9255 7500, or via [invest@platinum.com.au](mailto:invest@platinum.com.au).

**DISCLAIMERS:** The information presented in this Fact Sheet is general information only and not intended to be financial product advice. It has not been prepared taking into account any particular investor's or class of investors' investment objectives, financial situation or needs, and should not be used as the basis for making investment, financial or other decisions. You should read the entire PDS and consider your particular investment objectives, financial situation and needs prior to making any investment decision to invest (or divest) in the Fund. You should also obtain professional advice prior to making an investment decision. Some numerical figures in this Fact Sheet have been subject to rounding adjustments.

No company or any directors of any company in the Platinum Group® guarantees the performance of the Fund, the repayment of capital, or the payment of income. To the extent permitted by law, no liability is accepted by any company in the Platinum Group or their directors for any loss or damage as a result of any reliance on this information.

1. Investment returns are calculated using the Fund's unit price and represent the combined income and capital return for the specified period. They are net of fees and costs (excluding the buy-sell spread and any investment performance fee payable), pre-tax, and assume the reinvestment of distributions. The investment returns shown are historical and no warranty can be given for future performance. You should be aware that historical performance is not a reliable indicator of future performance. Due to the volatility of underlying assets of the Fund and other risk factors associated with investing, investment returns can be negative (particularly in the short-term).

2. The investment returns depicted in this graph are cumulative on A\$20,000 invested in the Fund since inception relative to the MSCI All Country World Health Care Net Index in A\$ ("Index"). The investment returns are calculated using the Fund's unit price. They are net of fees and costs (excluding the buy-sell spread and any investment performance fee payable), pre-tax and assume the reinvestment of distributions. It should be noted that Platinum does not invest by reference to the weightings of the Index. Underlying assets are chosen through Platinum's individual stock selection process and as a result holdings will vary considerably to the make-up of the Index. The Index is provided as a reference only.

3. The "Long %" represents the exposure of physical holdings and long stock derivatives as a % of the Fund's net asset value. The "Net %" represents the exposure of physical holdings and both long and short derivatives as a % of the Fund's net asset value. The "Currency %" represents the currency exposure for the Fund as a % of the Fund's net asset value, taking into account currency hedging.

4. Top Ten positions shows the Fund's top long share exposure positions as a % of the Fund's net asset value. Long derivative exposures are included, however, short derivative exposures are not.